From measuring anaemia in a clinic to monitoring diabetes, quick, reliable diagnostic tests are vital to modern healthcare. EKF Diagnostics (LSE:EKF) makes point-of-care analysers and related products used around the world. After a year of steady growth and improving margins, the question is what could make diagnostic testing an even stronger Earnings engine for the company.
A point-of-care diagnostics specialist
EKF Diagnostics, listed on London’s AIM, develops and manufactures point-of-care diagnostic devices and related products, alongside a life-sciences business. Its point-of-care analysers measure markers such as haemoglobin, glucose and other indicators quickly at the patient’s side, used in clinics, hospitals and health programmes worldwide. The life-sciences arm supplies products and services to other manufacturers and researchers. This combination gives EKF a base of recurring consumable sales tied to its installed analysers, plus Manufacturing and life-sciences income, spread across many markets.
The 2025 results
For the year to 31 December 2025, EKF reported Revenue of about £51.6 million, up around 2.8%, with point-of-care revenue of roughly £33.0 million and life sciences about £17.9 million. Gross Margin improved to around 51%, and adjusted EBITDA rose about 9.3% to roughly £12.4 million, with pre-tax profit of about £7.1 million. Cash stood at around £15.8 million, and operating cash generation was strong. EKF paused dividends to focus on growth, instead returning about £5.0 million through share Buybacks during the year.
The value of consumables
A key strength of diagnostics is recurring consumable revenue. Once EKF’s analysers are installed in clinics and hospitals, they require ongoing purchases of test cartridges and reagents, generating steady, repeat income at attractive margins. Growing the installed base of analysers therefore builds a larger stream of recurring consumable sales over time. This razor-and-blade dynamic, combined with improving gross margins, is central to making diagnostics a strong earnings engine, as more devices in the field drive higher-margin consumable revenue that compounds year after year.
Levers to strengthen earnings
Several levers could boost earnings. Expanding the installed base of analysers, particularly in growing markets and health programmes, increases recurring consumable sales. Improving manufacturing efficiency and gross margins, as achieved in 2025, lifts profitability. Launching new or enhanced products, and connectivity features showcased at industry events, can win customers and add value. Growing the life-sciences Business and controlling costs help too. Disciplined Capital allocation, using cash for buybacks and growth, supports returns. Together, these could turn steady diagnostics into a more powerful, higher-margin earnings engine.
The risks to weigh
Risks apply. The diagnostics market is competitive, with larger rivals, so EKF must keep innovating and winning placements. Healthcare budgets and procurement cycles can affect demand, and reliance on certain products or markets concentrates risk. It has exposure in Russia, with some restricted cash, adding geopolitical uncertainty. Manufacturing and supply-chain issues, currency movements and regulatory requirements all affect the business. Growth has been modest, and pausing the Dividend signals a focus on reinvestment that must deliver. Turning steady revenue into materially stronger earnings requires consistent execution.
So what could strengthen the engine?
Diagnostic testing could become a stronger earnings engine as EKF expands its installed base and recurring consumable sales, improves margins and efficiency, launches new products, and allocates capital well, turning steady growth into higher, more durable profits. The 2025 results, with rising margins, growing EBITDA and strong cash generation, show progress. Competitive, budget and geopolitical risks are genuine, and growth has been modest. But with a razor-and-blade model and improving profitability, EKF has credible ways to strengthen its earnings over time. Investors should watch the installed base, consumable revenue and margins as the clearest guides to whether the earnings engine is genuinely strengthening.






Please wait processing your request...